Core Insights - QuidelOrtho reported $2.73 billion in revenue for the full year, with non-respiratory revenue growing 5% and Labs business growing 6%, representing 55% of total revenue [1][6] - The company experienced a decline in respiratory revenue, totaling $402 million, primarily due to lower COVID testing [1][6] Financial Performance - For Q4, QuidelOrtho reported revenue of $724 million, a 2% year-over-year increase; excluding COVID and donor screening, revenue growth was 7% [2] - The company achieved $140 million in cost savings, expanded adjusted EBITDA margins to the low 20% range, and reported an adjusted EBITDA margin of 22% for 2025, a 240 basis point improvement year-over-year [3][6] - Adjusted diluted EPS was $0.46 in Q4 and $2.12 for the full year, representing a 15% growth year-over-year [6] Segment and Regional Performance - Labs revenue grew 7% in Q4 and 6% for the full year, driven by strength in clinical chemistry; respiratory revenue declined 14% in Q4 and 20% for the year [8][9] - North America revenue was up 4% in Q4 but down 2% for the year; Europe, Middle East, and Africa was flat in Q4 and up 4% for the year [9] Research and Development - Recent FDA clearances include a high-sensitivity Troponin I assay and a DAT direct anticoagulant test card; plans for the launch of the VITROS 450 platform are underway [5][10] - The Lex molecular platform is in the final stages of FDA review, designed for point-of-care applications [13] 2026 Outlook - Management guided for 2026 revenue of $2.7 billion to $2.9 billion, with expected growth in Labs and Immunohematology, and a decline in molecular diagnostics due to the discontinuation of the Savanna business [17][18] - Adjusted EBITDA is expected to be between $630 million and $670 million, implying an adjusted EBITDA margin of about 23.3% [19] Leadership Update - The CFO, Joe Busky, will retire in June, and the company has initiated a search for a successor [20]

Core Insights - QuidelOrtho's shares fell 12.8% after disappointing Q3 financial results and a reduced full-year earnings forecast [1] - The company's Q3 revenue was $699.9 million, a 3.7% decrease year-over-year, despite adjusted earnings per share of $0.80 beating Wall Street expectations [1] - A significant GAAP net loss, including a non-cash goodwill impairment charge, raised investor concerns [1] - QuidelOrtho lowered its adjusted earnings per share guidance for the full year by 10.6% at the midpoint [1] Market Reaction - QuidelOrtho's shares have shown extreme volatility, with 35 moves greater than 5% in the past year, indicating significant market impact from recent news [3] - The previous notable stock movement occurred 17 days prior, when shares gained 5.5% following positive news regarding the company's commitment to transfusion medicine and FDA approval of a new product [4] Stock Performance - Since the beginning of the year, QuidelOrtho's stock has declined by 47.9%, currently trading at $23.47, which is 50.7% below its 52-week high of $47.61 [5] - An investment of $1,000 in QuidelOrtho shares five years ago would now be worth $82.80 [5]

Core Insights - GE HealthCare Technologies (GEHC) reported quarterly earnings of $1.07 per share, exceeding the Zacks Consensus Estimate of $1.05 per share, but down from $1.14 per share a year ago, indicating an earnings surprise of +1.90% [1] - The company achieved revenues of $5.14 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.48% and up from $4.86 billion year-over-year [2] - GE HealthCare has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] Financial Performance - The earnings surprise of +16.48% was noted in the previous quarter, where actual earnings were $1.06 compared to an expected $0.91 [1] - The current consensus EPS estimate for the upcoming quarter is $1.41, with projected revenues of $5.6 billion, while the estimate for the current fiscal year is $4.53 on revenues of $20.45 billion [7] Market Position - GE HealthCare shares have increased by approximately 1.6% since the beginning of the year, contrasting with the S&P 500's gain of 17.2% [3] - The Zacks Rank for GE HealthCare is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Products industry, to which GE HealthCare belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of GE HealthCare's stock may be influenced by the overall outlook for the industry [8]

Core Viewpoint - The Meridian Contrarian Fund reported a strong performance in Q2 2025, with a return of 16.42%, outperforming the Russell 2500 Index and the Russell 2500 Value Index, amidst a significant recovery in the U.S. equity market, which rose 23% during the quarter [1] Group 1: Fund Performance - The U.S. large-cap stocks gained 11.1% in Q2 2025, with growth stocks outperforming value stocks [1] - The Meridian Contrarian Fund's return of 16.42% (net) exceeded the Russell 2500 Index's return of 8.59% and the Russell 2500 Value Index's return of 7.29% [1] Group 2: QuidelOrtho Corporation (NASDAQ:QDEL) - QuidelOrtho Corporation is a diagnostic testing solutions provider, with a one-month return of -7.51% and a 52-week loss of 41.75%, closing at $26.53 per share on September 25, 2025, with a market capitalization of $1.802 billion [2] - The Meridian Contrarian Fund invested in QuidelOrtho following its merger with Ortho Clinical Diagnostics, believing it positioned the company for improved growth and margins [3] - Despite the company's earnings being in line with expectations, broader macro concerns affected its stock performance, particularly in the respiratory business and potential funding cuts in government health programs [3] Group 3: Hedge Fund Interest - QuidelOrtho Corporation was held by 31 hedge fund portfolios at the end of Q2 2025, a decrease from 32 in the previous quarter [4] - The company reported Q2 revenue of $614 million, down from $637 million in the prior year [4]

Core Viewpoint - Medtronic's recent earnings report shows a positive trend in earnings and revenues, but there are concerns about future performance as estimates have trended downward recently [1][10][12]. Financial Performance - Medtronic reported Q1 fiscal 2026 adjusted earnings per share of $1.26, a 2.4% increase from the previous year, beating estimates by 2.4% [2]. - Worldwide revenues reached $8.58 billion, reflecting an 8.3% year-over-year increase and surpassing estimates by 2.5% [3]. Segmental Analysis - Cardiovascular segment revenues grew 7% organically to $3.23 billion, with Cardiac Rhythm & Heart Failure sales at $1.71 billion, up 9.1% [4]. - Medical Surgical revenues totaled $2.08 billion, a 2.4% organic increase, while Neuroscience revenues were $2.42 billion, up 3.1% [5][6]. Margin Performance - Gross margin contracted by 10 basis points to 65%, attributed to an 8.7% rise in revenue costs [7]. - Adjusted operating margin improved by 81 basis points to 23.8% [7]. Fiscal 2026 Outlook - Medtronic projects organic revenue growth of 5% for fiscal 2026, with reported revenue growth expected to be between 6.5% and 6.8% [8][9]. - The Zacks Consensus Estimate for fiscal 2026 revenues is $35.29 billion, indicating a 5.2% growth from the previous year [9]. Estimate Revisions - Estimates for Medtronic have trended downward over the past month, indicating a potential shift in market expectations [10][12]. Industry Comparison - Medtronic operates within the Zacks Medical - Products industry, where competitor QuidelOrtho has seen a 9.1% gain over the past month [13].

Core Viewpoint - QuidelOrtho Corporation (NASDAQ:QDEL) is recognized as one of the best small-cap stocks to buy, with RBC Capital raising its price target from $60 to $62 while maintaining a Buy rating [1][3]. Financial Performance and Strategy - QuidelOrtho has successfully completed a series of transactions to refinance its debt structure, extending debt maturities and reducing required amortization payments, which enhances financial flexibility [2][3]. - The company prioritizes reducing total debt and net debt leverage, improving debt covenant terms, and enhancing cash flow to support future growth [3]. Market Growth and Opportunities - The company has experienced significant growth in international markets during Q2 FY2025, particularly in Latin America, Japan, Asia Pacific, and EMEA regions [4]. - QuidelOrtho is focusing on its molecular strategy, including the acquisition of LEX Diagnostics, which is expected to enhance its growth potential [4]. Analyst Insights - As of September 5, the average price target for QuidelOrtho is $37.50, indicating an upside potential of approximately 30.75% from current levels [5]. - QuidelOrtho operates in various segments, including Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics [5].

Core Insights - The collaboration between QuidelOrtho and BÜHLMANN Laboratories AG focuses on addressing key healthcare trends such as non-invasive diagnostic tools, cost-effective healthcare solutions, and the emphasis on gastrointestinal and pancreatic health [1][4] - The fCAL and fPELA turbo assays represent significant advancements in the diagnosis of inflammatory bowel disease (IBD) and pancreatic insufficiency, providing fast results that enhance patient care [2][4] - The integration of CALEX Cap technology simplifies sample extraction and preparation, improving operational efficiency and clinical accuracy [3][4] Company Overview - QuidelOrtho Corporation is a leader in in vitro diagnostics, offering solutions that transform data into actionable insights across various healthcare settings [6][7] - BÜHLMANN Laboratories AG has been developing innovative in-vitro diagnostic assays for nearly 50 years, focusing on chemistry and immunological testing [9] Product Features - The fCAL and fPELA turbo assays provide rapid results in less than 10 minutes, with a 90-day on-analyzer stability and compatibility with VITROS Automation Solutions [8] - The collaboration enhances flexibility in sample handling and processing, catering to a wide variety of sample collection methods [4]

Group 1: CrowdStrike Holdings, Inc. - CrowdStrike reported better-than-expected earnings for the first quarter and raised its full-year guidance [2] - The company expects second-quarter revenue to be between $1.145 billion and $1.152 billion, lower than the estimated $1.23 billion [2] - Anticipated second-quarter adjusted earnings are projected to be between 82 cents and 84 cents per share, compared to estimates of 92 cents per share [2] - Following the earnings report, CrowdStrike shares fell 7% to $454.70 in pre-market trading [2] Group 2: Other Companies - Asana, Inc. shares dipped 8.4% to $17.40 after reporting first-quarter results [5] - Outset Medical Inc. shares declined 6.8% to $18.09 after naming Renee Gaeta as CFO [5] - Merus NV shares fell 5.5% to $59.01 after pricing a $300 million public offering at $57 per share [5] - Quidelortho Corp shares decreased 4.3% to $29.00 in pre-market trading [5] - ATAI Life Sciences NV shares dropped 3.4% to $2.27 after a decline of more than 5% on Tuesday [5] - Doximity Inc. shares fell 2.7% to $52.06 after gaining around 4% on Tuesday [5]

Core Insights - The first-quarter reporting cycle shows a positive trend with most companies exceeding earnings estimates, although macroeconomic uncertainty is affecting future earnings outlooks [1] - The Medical sector is experiencing significant earnings growth, acting as a buffer against rising market volatility due to increasing tariffs [1][2] Medical Sector Performance - Key medical product companies are recovering from previous cost increases and supply-chain disruptions, with artificial intelligence integration expected to drive medical device adoption in 2025 [2] - At-home medical solutions are projected to continue their growth trend in 2025, despite potential negative impacts from rising tariffs [2] - As of April 30, 45% of Medical sector companies reported quarterly earnings, with 85.2% beating earnings estimates and 70.4% exceeding revenue expectations [3] - Year-over-year earnings in the Medical sector improved by 60.5%, while revenues increased by 7.8% [3] Earnings Expectations - The Medical sector's first-quarter earnings are anticipated to surge by 40%, with sales expected to rise by 8.3% year over year [4] - Hims & Hers Health is projected to report a first-quarter EPS of 14 cents, indicating a 180% growth from the previous year [8] - Globus Medical's first-quarter EPS is estimated at 74 cents, reflecting a 2.8% increase from the prior year [10] - QuidelOrtho's first-quarter EPS is expected to be 60 cents, showing a 36.4% improvement from the year-ago period [11] - Haemonetics is anticipated to report a first-quarter EPS of $1.22, suggesting a 35.6% increase from the previous year [12]